PMID- 35310186
OWN - NLM
STAT- MEDLINE
DCOM- 20220506
LR  - 20221205
IS  - 2040-2309 (Electronic)
IS  - 2040-2295 (Print)
IS  - 2040-2295 (Linking)
VI  - 2022
DP  - 2022
TI  - Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced 
      Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse 
      Reaction Rate.
PG  - 7898737
LID - 10.1155/2022/7898737 [doi]
LID - 7898737
AB  - PURPOSE: To explore the efficacy of crizotinib combined with chemotherapy in 
      treating advanced non-small-cell lung cancer (NSCLC) and its effect on patients' 
      quality of life (QOL) and adverse reaction rate (ARR). METHODS: 90 advanced NSCLC 
      patients admitted to our hospital (from 01, 2019 to 01, 2020) were chosen as the 
      research objects and randomly split into the control group (CG) and experimental 
      group (EG) by flipping a coin, with 45 cases each. Chemotherapy was performed to 
      CG, and the crizotinib treatment was introduced to EG on this basis, so as to 
      compare their clinical efficacy, ARR and 3-year survival rate, and QOL before and 
      after intervention by the Generic Quality of Life Inventory-74 (GQOLI-74). 
      RESULTS: Compared with CG, EG after treatment obtained obviously higher total 
      clinical effective rate (P < 0.001), lower total ARR (P < 0.05), higher GQOLI-74 
      scores (P < 0.001), and higher 3-year survival rate (P < 0.05). CONCLUSION: 
      Combining crizotinib with chemotherapy to advanced NSCLC patients can effectively 
      improve the patients' level of quality of life, prolong the long-term survival 
      rate, and present a better effect than single chemotherapy. Further study is 
      conducive to establishing a better treatment scheme for advanced NSCLC patients.
CI  - Copyright (c) 2022 Zaiqi Ma et al.
FAU - Ma, Zaiqi
AU  - Ma Z
AUID- ORCID: 0000-0003-4246-0745
AD  - Cardiothoracic Surgery, Qingdao Hospital of Traditional Chinese Medicine (Qingdao 
      Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China.
FAU - Wang, Yun
AU  - Wang Y
AUID- ORCID: 0000-0001-9662-2899
AD  - Thoracic Surgery, No. 971 Hospital of PLA Navy, 22 Minjiang Road, Shinan 
      District, Qingdao City, Shandong Province, China.
FAU - Sun, Yonghua
AU  - Sun Y
AUID- ORCID: 0000-0001-8648-8964
AD  - Pharmacy Department, Qingdao Hospital of Traditional Chinese Medicine (Qingdao 
      Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China.
FAU - Lin, Gaoyang
AU  - Lin G
AD  - Cardiothoracic Surgery, Qingdao Hospital of Traditional Chinese Medicine (Qingdao 
      Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China.
FAU - Zhao, Zhenqing
AU  - Zhao Z
AUID- ORCID: 0000-0002-8053-1324
AD  - Cardiothoracic Surgery, Qingdao Hospital of Traditional Chinese Medicine (Qingdao 
      Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220310
PL  - England
TA  - J Healthc Eng
JT  - Journal of healthcare engineering
JID - 101528166
RN  - 53AH36668S (Crizotinib)
SB  - IM
RIN - J Healthc Eng. 2022 Nov 23;2022:9834370. PMID: 36465246
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/etiology
MH  - Crizotinib/therapeutic use
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Quality of Life
PMC - PMC8930210
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/03/22 06:00
MHDA- 2022/05/07 06:00
PMCR- 2022/03/10
CRDT- 2022/03/21 08:59
PHST- 2021/12/02 00:00 [received]
PHST- 2021/12/24 00:00 [revised]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/03/21 08:59 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/05/07 06:00 [medline]
PHST- 2022/03/10 00:00 [pmc-release]
AID - 10.1155/2022/7898737 [doi]
PST - epublish
SO  - J Healthc Eng. 2022 Mar 10;2022:7898737. doi: 10.1155/2022/7898737. eCollection 
      2022.